Experts outline health care, policy and social changes needed to make the most of Alzheimer’s treatment breakthroughs

The approval of new antibody medications for Alzheimer’s disease—lecanemab and donanemab—and diagnostic tests in the blood mark the beginning of a new era in Alzheimer’s disease diagnosis and treatment. However, without rapid reform in health care systems, public policy, and societal attitudes, their potential will not be fully realized, argue 40 leading Alzheimer’s disease experts in The Lancet Series on Alzheimer’s disease.

Facebook Comments